MeiraGTx Holdings plc MGTX
8.14 USD -0.18 (-2.16%)
Regular-session close
8.14 0.00 0.00%
After hours · Nov 19, 4:01 PM ET
8.08 Day range 8.53
6.62 52-week range 15.35
- YTD
- +2.39%
- 1 year
- +7.39%
News
globenewswire.com MeiraGTx Announces Oral Presentation at ObesityWeek 2026 Presentation highlights the Company's AAV-BDNF program for the treatment of severe early-onset obesity Presentation highlights the Company's AAV-BDNF program for the treatment of severe early-onset…
zacks.com MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.62 per share a year ago.benzinga.com MeiraGTx Hldgs Q3 EPS $(0.53) Misses $(0.50) Estimate, Sales $4.814M Miss $6.953M Estimate MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.50) by 6 percent. This is a 14.52 percent increase over losses of…
globenewswire.com MeiraGTx Reports Third Quarter 2026 Financial and Operational Results Submission of Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)…
defenseworld.net MeiraGTx Holdings PLC $MGTX Shares Acquired by Alps Advisors Inc. Alps Advisors Inc. boosted its position in MeiraGTx Holdings PLC (NASDAQ: MGTX) by 84.9% during the undefined quarter, according to the company in its most recent disclosure with the Securities and…
globenewswire.com MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting Multiple Posters Highlight the Breadth of Company's Novel Genetic Medicine and Cell Therapy Platforms Multiple Posters Highlight the Breadth of Company's Novel Genetic Medicine and Cell Therapy…
defenseworld.net Financial Contrast: MeiraGTx (NASDAQ:MGTX) & aTyr Pharma (NASDAQ:ATYR) MeiraGTx (NASDAQ: MGTX - Get Free Report) and aTyr Pharma (NASDAQ: ATYR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies…
globenewswire.com MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of…
defenseworld.net Head-To-Head Analysis: Ascendis Pharma A/S (NASDAQ:ASND) versus MeiraGTx (NASDAQ:MGTX) Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) and MeiraGTx (NASDAQ: MGTX - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two…
gurufocus.com Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in S
prnewswire.com Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD)…
zacks.com MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of a loss of $0.39 per share. This compares to a loss of $0.48 per share a year…
globenewswire.com MeiraGTx Reports Second Quarter 2026 Financial and Operational Results Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe…
prnewswire.com Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia Graviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026. FDA clearance marks a critical…
globenewswire.com MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation…
seekingalpha.com Some Potential Merit Within MeiraGTx Holdings MeiraGTx Holdings plc is positioned potentially for significant upside with late-stage gene therapy assets targeting large, high-unmet-need indications. AAV2-hAQP1 for radiation-induced xerostomia…
zacks.com Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High? The mean of analysts' price targets for MeiraGTx (MGTX) points to a 128.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among…
fool.com What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near Stuart Naylor liquidated 27,659 shares for $409,000 on July 7, 2026, at a weighted average price of $14.80 per share. The transaction resulted in a 4% reduction of the insider's total direct equity…
zacks.com MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last? MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase…
globenewswire.com MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec) LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced that it has entered…
seekingalpha.com MeiraGTx: The Market Is Missing The Manufacturing Pivot MeiraGTx is evolving into a late-stage, manufacturing-enabled genetic medicine company with multiple near-term regulatory catalysts. MGTX's robust manufacturing infrastructure and targeted therapies,…
